Phase I/II study of gemcitabine and exisulind as second-line therapy in patients with advanced non-small cell lung cancer

Journal of Thoracic Oncology

Volumn 1, Issue 3, 2006, Pages 218-225

  Hoang, Tien ^a   Kim, Kyungmann ^b   Merchant, Joseph ^b   Traynor, Anne M ^b   McGovern, James ^b   Oettel, Kurt R ^b   Sanchez, Fredrico A ^b   Ahuja, Harish G ^b   Hensing, Thomas A ^b   Larson, Martha ^b   Schiller, Joan H ^b  

^a OHIO STATE UNIVERSITY   (United States)

^b UNIVERSITY OF WISCONSIN   (United States)

Author keywords

Exisulind; Gemcitabine; Progressing non small cell lung cancer; Second line therapy

Indexed keywords

CARBOPLATIN; GEMCITABINE; NAVELBINE; PACLITAXEL; SULINDAC SULFONE; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; SULINDAC;

ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOPENIA; DRUG DOSE ESCALATION; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GRANULOCYTOPENIA; HUMAN; INFECTION; LIVER FUNCTION; LUNG NON SMALL CELL CANCER; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NEUTROPHIL COUNT; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; THROMBOCYTE COUNT; VOMITING; CHEMICALLY INDUCED DISORDER; DISEASE COURSE; FOLLOW UP; LUNG TUMOR; MIDDLE AGED; MORTALITY; SURVIVAL; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DEOXYCYTIDINE; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEUTROPENIA; SULINDAC; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VOMITING;

EID: 34247857630     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1016/S1556-0864(15)31571-9     Document Type: Article

References (43)

1. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-98.
2. Kelly K, Crowley J, Bunn PA, et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: A Southwest Oncology Group Trial. J Clin Oncol 2001;19:3210-3218.
3. Fossella F, Pereira JR, von Pawel J, et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: The TAX 326 study group. J Clin Oncol 2003;21:3016-3024.
4. Shepherd F, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18:2095-2103.
5. Fossella F, Devore R, Kerr RN, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with plantinum-containing chemotherapy regimens: The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 2000;18:2354-2362.
6. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22:1589-1597.
7. Le Chevalier T, Scagliotti G, Natale R, et al. Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: A meta-analysis of survival outcomes. Lung Cancer 2006;47:69-80.
8. Thompson WJ, Piazza GA, Li H, et al. Exisulind induction of apoptosis involves guanosine 3′,5′-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated beta-catenin. Cancer Res 2000;60:3338-3342.
9. Soh JW, Mao Y, Kim MG, et al. Cyclic GMP mediates apoptosis induced by sulindac derivatives via activation of c-Jun NH2-terminal kinase 1. Clin Cancer Res 2000;6:4136-4141.
10. Whitehead CM, Earle KA, Fetter J, et al. Exisulind-induced apoptosis in a non-small cell lung cancer orthotopic lung tumor model augments docetaxel treatment and contributes to increased survival. Mol Cancer Ther 2003;2:479-488.
11. Chan DC, Earle KA, Zhao TL, et al. Exisulind in combination with docetaxel inhibits growth and metastasis of human lung cancer and prolongs survival in athymic nude rats with orthotopic lung tumors. Clin Cancer Res 2002;8:904-912.
12. Joe AK, Liu H, Xiao D, et al. Exisulind and CP248 induce growth inhibition and apoptosis in human esophageal adenocarcinoma and squamous carcinoma cells. J Exp Ther Oncol 2003;3:83-94.
13. Piazza GA, Thompson WJ, Pamukcu R, et al. Exisulind, a novel proapoptotic drug, inhibits rat urinary bladder tumorigenesis. Cancer Res 2001;61:3961-3968.
14. Schiller J, Bittner G. Exisulind enhances the growth inhibitory effects of gemcitabine and vinorelbine on human lung cancer cell lines. Ann Oncol 2000;11:140.
15. Schiller J, Purvis J, Bittner G. CP 461 is active alone and in combination with gemcitabine, vinorelbine or irinotecan in non-small cell lung cancer. Ann Oncol 2000;11:144.
16. Bunn PA Jr, Chan DC, Earle K, et al. Preclinical and clinical studies of docetaxel and exisulind in the treatment of human lung cancer. Semin Oncol 2002;29:87-94.
17. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.
18. Rosvold E, Langer CJ, Schilder R, et al. Salvage therapy with gemcitabine in advanced non-small cell lung cancer (NSCLC) progressing after prior carboplatin-paclitaxel (C-P). Proc Am Soc Clin Oncol 1998;17:467a.
19. Gridelli C, Perrone F, Gallo C, et al. Single-agent gemcitabine as second-line treatment in patients with advanced non small cell lung cancer (NSCLC): A phase II trial. Anticancer Res 1999;19:4535-4538.
20. Crino L, Mosconi AM, Scagliotti G, et al. Gemcitabine as second-line treatment for advanced non-small-cell lung cancer: A phase II trial. J Clin Oncol 1999;17:2081-2085.
21. Van Kooten M, Traine G, Cinat G, et al. Single-agent gemcitabine in pretreated patients with non-small-cell lung cancer: Results of an Argentinean multicentre phase II trial. Br J Cancer 1999;81:846-849.
22. van Putten JW, Baas P, Codrington H, et al. Activity of single-agent gemcitabine as second-line treatment after previous chemotherapy or radiotherapy in advanced non-small-cell lung cancer. Lung Cancer 2001;33:289-298.
23. Lara PN Jr, Gumerlock PH, Mack PC, et al. Gemcitabine in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: A phase II California cancer consortium trial. Clin Lung Cancer 2004;6:102-107.
24. Hainsworth JD, Burris HA III, Billings FT III, et al. Weekly docetaxel with either gemcitabine or vinorelbine as second-line treatment in patients with advanced nonsmall cell lung carcinoma: Phase II trials of the Minnie Pearl Cancer Research Network. Cancer 2001;92:2391-2398.
25. Kosmas C, Tsavaris N, Vadiaka M, et al. Gemcitabine and docetaxel as second-line chemotherapy for patients with nonsmall cell lung carcinoma who fail prior paclitaxel plus platinum-based regimens. Cancer 2001;92:2902-2910.
26. Kakolyris S, Papadakis E, Tsiafaki X, et al. Docetaxel in combination with gemcitabine plus rhG-CSF support as second-line treatment in non-small cell lung cancer: A multicenter phase II study. Lung Cancer 2001;32:179-187.
27. Niho S, Kubota K, Goto K, et al. Combination second-line chemotherapy with gemcitabine and docetaxel for recurrent non-small-cell lung cancer after platinum-containing chemotherapy: A phase I/II trial. Cancer Chemother Pharmacol 2003;52:19-24.
28. Kakolyris S, Georgoulias V. The role of gemcitabine and paclitaxel as second-line chemotherapy for the treatment of advanced non small-cell lung cancer (NSCLC). Clin Lung Cancer 2000;2:43-47.
29. Dongiovanni V, Addeo A, Berruti A, et al. A phase II trial of weekly paclitaxel and gemcitabine in non-small cell lung cancer patients previously treated with platinum and vinorelbine. Anticancer Res 2004;24:2567-2572.
30. Hainsworth JD, Burris HA III, Litchy S, et al. Gemcitabine and vinorelbine in the second-line treatment of nonsmall cell lung carcinoma patients: A Minnie Pearl cancer research network phase II trial. Cancer 2000;88:1353-1358.
31. Kosmas C, Tsavaris N, Panopoulos C, et al. Gemcitabine and vinorelbine as second-line therapy in non-small-cell lung cancer after prior treatment with taxane+platinum-based regimens. Eur J Cancer 2001;37:972-978.
32. Herbst RS, Khuri FR, Lu C, et al. The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma: Potential for decreased toxicity and combination with biological therapy. Cancer 2002;95:340-353.
33. Georgoulias V, Kouroussis C, Agelidou A, et al. Irinotecan plus gemcitabine vs irinotecan for the second-line treatment of patients with advanced non-small-cell lung cancer pretreated with docetaxel and cisplatin: A multicentre, randomised, phase II study. Br J Cancer 2004;91:482-488.
34. Shepherd F, Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small cell lung cancer. N Engl J Med 2006;353:123-132.
35. Sandler A, Gray R, Brahmer J. Randomized phase II/III Trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC # 704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) Trial - E4599. Proc Am Soc Clin Oncol 2006;23:2s.
36. van Stolk R, Stoner G, Hayton W, et al. Phase I trial of exisulind (sulindac sulfone, FGN-1) as a chemopreventive agent in patients with familial adenomatous polyposis. Clin Cancer Res 2000;6:78-89.
37. Kelly K, Mikhaeel N, Dempsey E, et al. A phase I study of exisulind in previously treated patients with lung cancer. Lung Cancer 2000;29:76.
38. Witta SE, Gustafson DL, Pierson AS, et al. A phase I and pharmacokinetic study of exisulind and docetaxel in patients with advanced solid tumors. Clin Cancer Res 2004;10:7229-7237.
39. Traynor AM, Merchant JJ, Hoang T, et al. Phase I/II study of exisulind (E) and vinorelbine (V) in elderly patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol (Proc Am Soc Clin Oncol) 2004;22:7272.
40. Pusztai L, Zhen JH, Arun B, et al. Phase I and II study of exisulind in combination with capecitabine in patients with metastatic breast cancer. J Clin Oncol 2003;21:3454-3461.
41. Jones SF, Kuhn JG, Greco FA, et al. A Phase I/II study of exisulind in combination with docetaxel/carboplatin in patients with metastatic non-small-cell lung cancer. Clin Lung Cancer 2006;6:361-366.
42. Masters G, Xu R, Langer C. A phase II trial of carboplatin and gemcitabine with exisulind (IND # 65,056) in patients with advanced non-small cell lung cancer: Eastern Cooperative Oncology Group Trial 1501. Pro Am Soc Clin Oncol 2004.
43. OSI-Pharmaceuticals. Aptosyn in combination with taxotere in advanced non-small cell lung cancer does not meet endpoints. OSI Pressroom. Accessed June 11, 2004 (http://www.corporate-ir.net/ireye/ir_site.zhtml?ticker= OSIP&script=410&layout=0&item_id=580958), 2004.